Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association

Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association

Safety monitoring is of paramount importance for vaccines authorized for emergent use (EUA) by the US Food and Drug Administration (FDA) against SARS-CoV-2. Mass immunization is an essential tool to end the current pandemic, but vaccine surveillance is necessary to identify any potentially associate...

Full description

Bibliographic Details
Main Authors: Osakpolor Ogbebor, Harshit Seth, Zaw Min, Nitin Bhanot
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:IDCases
Subjects:
SARS-CoV-2 vaccine
Guillain-Barré syndrome
Online Access:http://www.sciencedirect.com/science/article/pii/S2214250921000998
id doaj-98c90cbef76c47178053eee929c92eb6
record_format Article
spelling doaj-98c90cbef76c47178053eee929c92eb62021-06-17T04:47:24ZengElsevierIDCases2214-25092021-01-0124e01143Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal associationOsakpolor Ogbebor0Harshit Seth1Zaw Min2Nitin Bhanot3Division of Infectious Disease, Medicine Institute, Allegheny Health Network, Pittsburgh, PA 15212, United StatesDivision of Hospitalist Medicine, Medicine Institute, Allegheny Health Network, Pittsburgh, PA 15212, United StatesDivision of Infectious Disease, Medicine Institute, Allegheny Health Network, Pittsburgh, PA 15212, United StatesDivision of Infectious Disease, Medicine Institute, Allegheny Health Network, Pittsburgh, PA 15212, United States; Corresponding author at: Division of Infectious Disease, 420 East North Ave, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA 15212, United States.Safety monitoring is of paramount importance for vaccines authorized for emergent use (EUA) by the US Food and Drug Administration (FDA) against SARS-CoV-2. Mass immunization is an essential tool to end the current pandemic, but vaccine surveillance is necessary to identify any potentially associated harms. At the same time, probability of temporal bias should be borne in mind before making conclusions about causality between the vaccine and an attributable undesired effect. We report a case of Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine and believe this is a temporal, rather than causal association.http://www.sciencedirect.com/science/article/pii/S2214250921000998SARS-CoV-2 vaccineGuillain-Barré syndrome
collection DOAJ
language English
format Article
sources DOAJ
author Osakpolor Ogbebor
Harshit Seth
Zaw Min
Nitin Bhanot
spellingShingle Osakpolor Ogbebor
Harshit Seth
Zaw Min
Nitin Bhanot
Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association
IDCases
SARS-CoV-2 vaccine
Guillain-Barré syndrome
author_facet Osakpolor Ogbebor
Harshit Seth
Zaw Min
Nitin Bhanot
author_sort Osakpolor Ogbebor
title Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association
title_short Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association
title_full Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association
title_fullStr Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association
title_full_unstemmed Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association
title_sort guillain-barré syndrome following the first dose of sars-cov-2 vaccine: a temporal occurrence, not a causal association
publisher Elsevier
series IDCases
issn 2214-2509
publishDate 2021-01-01
description Safety monitoring is of paramount importance for vaccines authorized for emergent use (EUA) by the US Food and Drug Administration (FDA) against SARS-CoV-2. Mass immunization is an essential tool to end the current pandemic, but vaccine surveillance is necessary to identify any potentially associated harms. At the same time, probability of temporal bias should be borne in mind before making conclusions about causality between the vaccine and an attributable undesired effect. We report a case of Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine and believe this is a temporal, rather than causal association.
topic SARS-CoV-2 vaccine
Guillain-Barré syndrome
url http://www.sciencedirect.com/science/article/pii/S2214250921000998
work_keys_str_mv AT osakpolorogbebor guillainbarresyndromefollowingthefirstdoseofsarscov2vaccineatemporaloccurrencenotacausalassociation
AT harshitseth guillainbarresyndromefollowingthefirstdoseofsarscov2vaccineatemporaloccurrencenotacausalassociation
AT zawmin guillainbarresyndromefollowingthefirstdoseofsarscov2vaccineatemporaloccurrencenotacausalassociation
AT nitinbhanot guillainbarresyndromefollowingthefirstdoseofsarscov2vaccineatemporaloccurrencenotacausalassociation
_version_ 1721374429955489792

Similar Items